Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
474.6 USD | +0.20% |
|
-1.21% | +16.91% |
17/06 | Argus Adjusts Price Target on Vertex Pharmaceuticals to $550 From $465 | MT |
14/06 | Vertex Pharmaceuticals Says Gene-Editing Therapy Demonstrates Clinical Benefits in Genetic Disease Trials | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.91% | 122B | |
+19.11% | 113B | |
+2.30% | 22.66B | |
-16.77% | 21.34B | |
-39.57% | 16.92B | |
-14.17% | 16.68B | |
-16.31% | 16.61B | |
+2.72% | 13.62B | |
+21.30% | 11.04B | |
+108.71% | 10.43B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals Says Phase 3 Data Show Trikafta Improves Lung Function in Cystic Fibrosis Patients